Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins.
In: Journal of Investigative Medicine (Sage Publications Inc.), Jg. 66 (2018-03-01), Heft 3, S. 661-668
academicJournal
Zugriff:
Data on cytokeratin-18 (K-18) and enhanced liver fibrosis (ELF) score in insulin-treated diabetes patients with non-alcoholic fatty liver disease (NAFLD) are limited. This study analyzed phase III data comparing basal insulin peglispro (BIL) and insulin glargine in type 1 (T1D), and type 2 diabetes (T2D) (insulin-naïve and insulin-treated). Alanine aminotransferase (ALT), K-18, ELF scores and liver fat content (LFC), measured by MRI, were obtained longitudinally. Baseline K-18 (U/L) was higher in T2D (range: 207‒247) than T1D (range: 148‒183), correlated with ALT in all populations (r (range) 0.264‒0.637, p<0.05), but with LFC only in T2D (r (range) 0.474‒0.586, p<0.05). K-18 increased significantly from baseline in BIL-treated, but not glargine-treated patients. Change from baseline (CFB) K-18 was significantly correlated with CFB in ALT in BIL-treated T2D populations. Baseline ELF scores were higher in T2D (range: 9.12‒9.20) than T1D (range: 8.24‒8.36), correlated with ALT in T1D only (0.209, p<0.05), and not correlated with LFC in any population. ELF scores increased significantly from baseline in BIL-treated but not glargine-treated patients. There were no correlations between CFB in LFC and ELF score at week 52 in any treatment group/population. In all BIL-treated populations, CFB in ALT and CFB in ELF score at week 52 were positively correlated. These data characterize associations of K-18 and ELF score with ALT and LFC in insulin-treated patients with T1D and T2D. Hepatopreferential insulins may be associated with increased K-18 and ELF scores but mechanisms and clinical significance are unknown. ClinicalTrials.gov identifiers are NCT01481779, NCT01435616, NCT01454284 and NCT01582451. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Investigative Medicine (Sage Publications Inc.) is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins.
|
---|---|
Autor/in / Beteiligte Person: | Sanyal, Arun ; Cusi, Kenneth ; Hartman, Mark L. ; Zhang, Shuyu ; Bastyr, Edward J. ; Bue-Valleskey, Juliana M. ; Chang, Annette M. ; Haupt, Axel ; Jacober, Scott J. ; Konrad, Robert J. ; Zhang, Qianyi ; Hoogwerf, Byron J. ; Bastyr, Edward J 3rd |
Zeitschrift: | Journal of Investigative Medicine (Sage Publications Inc.), Jg. 66 (2018-03-01), Heft 3, S. 661-668 |
Veröffentlichung: | 2018 |
Medientyp: | academicJournal |
ISSN: | 1081-5589 (print) |
DOI: | 10.1136/jim-2017-000609 |
Schlagwort: |
|
Sonstiges: |
|